Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIL62 injection plus lenalidomide in relapsed/refractory follicular and marginal zone lymphoma
CTR20191390Phase 2Completed
- Sponsor
- Mabworks Biotech
- Start
- Dec 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Bejescin, lenalidomide in follicular lymphoma (FL), marginal zone B-cell lymphoma (MZL), splenic marginal zone lymphoma (SMZL), nodal marginal zone B-cell lymphoma (NMZL), sponsored by Mabworks Biotech. Started Dec 2019; status: completed.
02
Drugs
Bejescinlenalidomide
03
Conditions
follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)splenic marginal zone lymphoma (SMZL)nodal marginal zone B-cell lymphoma (NMZL)
Beyond the preview
Go deeper on CTR20191390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191390.